WAM
KTTAW icon

Warberg Asset Management’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Warberg Asset Management’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$2.03K – 199
2025
Q1 		$2.03K Sell
100,000
-154,701
-61% -$3.99K ﹤0.01% 180
2024
Q4 		$8.81K Sell
254,701
-8,300
-3% -$213 ﹤0.01% 166
2024
Q3 		$9.18K Sell
263,001
-15,683
-6% -$296 ﹤0.01% 170
2024
Q2 		$4.26K Sell
278,684
-11,184
-4% -$157 ﹤0.01% 194
2024
Q1 		$3.59K Hold
289,868
– – ﹤0.01% 184
2023
Q4 		$5.22K Hold
289,868
– – ﹤0.01% 189
2023
Q3 		$3.8K Sell
289,868
-100
-0% -$2 ﹤0.01% 210
2023
Q2 		$6.23K Hold
289,968
– – ﹤0.01% 192
2023
Q1 		$8.7K Hold
289,968
– – ﹤0.01% 197
2022
Q4 		$9.55K Sell
289,968
-20,915
-7% -$1.22K ﹤0.01% 206
2022
Q3 		$40K Sell
310,883
-300
-0.1% -$30 0.01% 181
2022
Q2 		$20K Buy
311,183
+11,275
+4% +$1.41K ﹤0.01% 184
2022
Q1 		$51K Buy
299,908
+80,988
+37% +$19.3K 0.01% 160
2021
Q4 		$81K Buy
+218,920
New +$108K 0.02% 139

Other funds holding KTTAW

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Warberg Asset Management's KTTAW Position: Q2 2025 in Review

Warberg Asset Management sold out of Pasithea Therapeutics Warrants (KTTAW) in Q2 2025, closing a stake of 100,000 shares — an estimated $2.03K sold.

Warberg Asset Management first reported a position in KTTAW in Q4 2021 and held it in 14 quarters. The position peaked at $81K in Q4 2021. 5 funds tracked by Wall St. Rank hold KTTAW as of Q2 2025.

  • Warberg Asset Management reported no remaining Pasithea Therapeutics Warrants position as of Q2 2025 after selling out during the quarter.
  • Warberg Asset Management sold 100,000 Pasithea Therapeutics Warrants shares in Q2 2025, an estimated $2.03K.
  • Warberg Asset Management first reported a position in Pasithea Therapeutics Warrants in Q4 2021 and held it in 14 quarters.
  • Warberg Asset Management's Pasithea Therapeutics Warrants position peaked at $81K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q2 2025.

Based on Warberg Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.